JP2019505521A5 - - Google Patents

Download PDF

Info

Publication number
JP2019505521A5
JP2019505521A5 JP2018536444A JP2018536444A JP2019505521A5 JP 2019505521 A5 JP2019505521 A5 JP 2019505521A5 JP 2018536444 A JP2018536444 A JP 2018536444A JP 2018536444 A JP2018536444 A JP 2018536444A JP 2019505521 A5 JP2019505521 A5 JP 2019505521A5
Authority
JP
Japan
Prior art keywords
egf
seq
formula
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018536444A
Other languages
English (en)
Other versions
JP2019505521A (ja
JP6797926B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/050668 external-priority patent/WO2017121850A1/en
Publication of JP2019505521A publication Critical patent/JP2019505521A/ja
Publication of JP2019505521A5 publication Critical patent/JP2019505521A5/ja
Application granted granted Critical
Publication of JP6797926B2 publication Critical patent/JP6797926B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (2)

  1. 配列番号1によって定義されるLDL-RのEGF(A)ドメインのEGF(A)ペプチド類似体を含むEGF(A)誘導体であって、
    i.
    Figure 2019505521
     （式中、前記EGF(A)ペプチド類似体のアミノ酸配列は、配列番号32である）、
    ii.
    Figure 2019505521
     （式中、前記EGF(A)ペプチド類似体のアミノ酸配列は、配列番号76である）、
    iii.
    Figure 2019505521
     （式中、前記EGF(A)ペプチド類似体のアミノ酸配列は、配列番号32である）、
    iv.
    Figure 2019505521
     （式中、前記EGF(A)ペプチド類似体のアミノ酸配列は、配列番号98である）、
    v.
    Figure 2019505521
     （式中、前記EGF(A)ペプチド類似体のアミノ酸配列は、配列番号98である）、
    vi.
    Figure 2019505521
     （式中、前記EGF(A)ペプチド類似体のアミノ酸配列は、配列番号98である）、
    vii.
    Figure 2019505521
     （式中、前記EGF(A)ペプチド類似体のアミノ酸配列は、配列番号78である）、
    viii.
    Figure 2019505521
     （式中、前記EGF(A)ペプチド類似体のアミノ酸配列は、配列番号104である）、
    ix.
    Figure 2019505521
     （式中、前記EGF(A)ペプチド類似体のアミノ酸配列は、配列番号72である）、
    x.
    Figure 2019505521
     （式中、前記EGF(A)ペプチド類似体のアミノ酸配列は、配列番号105である）
    からなる群から選択される、EGF(A)誘導体。
  2. 前記誘導体が、
    Figure 2019505521
     であり、前記EGF(A)ペプチド類似体の配列が、配列番号104である、請求項1に記載のEGF(A)誘導体。
JP2018536444A 2016-01-13 2017-01-13 脂肪酸置換基を有するｅｇｆ（ａ）類似体 Active JP6797926B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/070791 2016-01-13
CN2016070791 2016-01-13
CNPCT/CN2016/076580 2016-03-17
CN2016076580 2016-03-17
EP16195965 2016-10-27
EP16195965.5 2016-10-27
PCT/EP2017/050668 WO2017121850A1 (en) 2016-01-13 2017-01-13 Egf(a) analogues with fatty acid substituents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020190846A Division JP2021035989A (ja) 2016-01-13 2020-11-17 脂肪酸置換基を有するｅｇｆ（ａ）類似体

Publications (3)

Publication Number Publication Date
JP2019505521A JP2019505521A (ja) 2019-02-28
JP2019505521A5 true JP2019505521A5 (ja) 2020-06-18
JP6797926B2 JP6797926B2 (ja) 2020-12-09

Family

ID=57868232

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018536444A Active JP6797926B2 (ja) 2016-01-13 2017-01-13 脂肪酸置換基を有するｅｇｆ（ａ）類似体
JP2020190846A Withdrawn JP2021035989A (ja) 2016-01-13 2020-11-17 脂肪酸置換基を有するｅｇｆ（ａ）類似体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020190846A Withdrawn JP2021035989A (ja) 2016-01-13 2020-11-17 脂肪酸置換基を有するｅｇｆ（ａ）類似体

Country Status (26)

Country Link
US (2) US10822385B2 (ja)
EP (1) EP3402811B1 (ja)
JP (2) JP6797926B2 (ja)
KR (1) KR102417487B1 (ja)
CN (1) CN108473550B (ja)
AU (1) AU2017207862B2 (ja)
BR (1) BR112018013820A2 (ja)
CA (1) CA3010756A1 (ja)
CL (1) CL2018001868A1 (ja)
CO (1) CO2018007440A2 (ja)
DK (1) DK3402811T3 (ja)
ES (1) ES2916998T3 (ja)
HR (1) HRP20220720T1 (ja)
HU (1) HUE058647T2 (ja)
IL (1) IL260043A (ja)
LT (1) LT3402811T (ja)
MX (1) MX2018008681A (ja)
MY (1) MY195199A (ja)
PE (1) PE20181376A1 (ja)
PH (1) PH12018501502A1 (ja)
PL (1) PL3402811T3 (ja)
RS (1) RS63298B1 (ja)
RU (1) RU2747877C2 (ja)
SA (1) SA518391996B1 (ja)
SI (1) SI3402811T1 (ja)
WO (1) WO2017121850A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2797904T3 (es) 2016-01-13 2020-12-04 Gruenenthal Gmbh Derivados de 3-((hetero)aril)alquil-8-amino-2-oxo-1,3-diazaespiro-[4.5]-decano
WO2017121850A1 (en) 2016-01-13 2017-07-20 Novo Nordisk A/S Egf(a) analogues with fatty acid substituents
RS60307B1 (sr) 2016-01-13 2020-07-31 Gruenenthal Gmbh Derivati 3-((hetero-)aril)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
AR107358A1 (es) 2016-01-13 2018-04-25 Gruenenthal Gmbh Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
RS60855B1 (sr) 2016-01-13 2020-10-30 Gruenenthal Gmbh Derivati 8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
US11130794B2 (en) 2017-07-19 2021-09-28 Novo Nordisk A/S Bifunctional compounds
CN111164098A (zh) * 2017-07-19 2020-05-15 诺沃挪第克公司 Egf(a)类似物、其制品、制剂和用途
WO2019023295A1 (en) * 2017-07-27 2019-01-31 Saint Louis University HUMAN EPIDERMAL GROWTH FACTOR MODIFIED BY FATTY ACID
TW202028229A (zh) 2018-10-05 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 包含胰島素肽及ｅｇｆ（ａ）肽之雙功能化合物
CN113508426A (zh) 2019-03-22 2021-10-15 3M创新有限公司 具有监测系统的坠落保护系统
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
WO2021023855A1 (en) 2019-08-07 2021-02-11 Novo Nordisk A/S Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
PE20221458A1 (es) 2019-11-07 2022-09-21 Novo Nordisk As Composiciones solidas que comprenden un inhibidor de pcsk9 y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080050576A (ko) 2005-07-29 2008-06-09 앰프로틴 코포레이션 키메릭 치료제
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
JP5721432B2 (ja) * 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
EP2296694B1 (en) * 2008-04-23 2015-08-05 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
US8673850B2 (en) 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
WO2012017774A1 (ja) * 2010-08-02 2012-02-09 日本電気株式会社 偏光子及び発光装置
CN102153652A (zh) 2010-12-10 2011-08-17 浙江大学 一种融合蛋白的表达方法及用途
JP2014510516A (ja) * 2011-02-15 2014-05-01 ノヴォ ノルディスク アー／エス 長時間作用性ｉｌ−１受容体アンタゴニスト
RU2014101501A (ru) * 2011-06-20 2015-07-27 Дженентек, Инк. Связывающие pcsk9 полипептиды и способы применения
CA2849673A1 (en) * 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
CN104364262A (zh) * 2011-12-21 2015-02-18 诺沃—诺迪斯克有限公司 N末端修饰的胰岛素衍生物
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
AR092076A1 (es) 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
SG11201500682WA (en) 2012-09-07 2015-02-27 Sanofi Sa Fusion proteins for treating a metabolic syndrome
KR20160021758A (ko) * 2013-04-18 2016-02-26 노보 노르디스크 에이/에스 의학용으로 사용하기 위한 안정하고 연장된 glp-1/글루카곤 수용체 코-아고니스트
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
RU2016137264A (ru) 2014-02-21 2018-03-26 МЕДИММЬЮН, ЭлЭлСи Слияния антитела к pcsk9~glp-1 и способы применения
US10570184B2 (en) * 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
CN104558198A (zh) 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
CA2979617C (en) * 2015-03-19 2024-01-02 Institut De Cardiologie De Montreal Grp94 derived polypeptides for inhibiting pcsk9 and methods of use
CN105367884A (zh) 2015-11-02 2016-03-02 陈薇 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法
WO2017121850A1 (en) 2016-01-13 2017-07-20 Novo Nordisk A/S Egf(a) analogues with fatty acid substituents
US11130794B2 (en) 2017-07-19 2021-09-28 Novo Nordisk A/S Bifunctional compounds
CN111164098A (zh) 2017-07-19 2020-05-15 诺沃挪第克公司 Egf(a)类似物、其制品、制剂和用途

Similar Documents

Publication Publication Date Title
JP2019505521A5 (ja)
JP2018536572A5 (ja)
JP2019194236A5 (ja)
JP2011527560A5 (ja)
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
JP2016525888A5 (ja)
JP2015513533A5 (ja)
JP2015038108A5 (ja)
JP2016535744A5 (ja)
JP2017534262A5 (ja)
JP2017523796A5 (ja)
JP2016520672A5 (ja)
WO2016077464A8 (en) Amino acid derivatives and their uses
JP2014224126A5 (ja)
JP2015518463A5 (ja)
JP2015180693A5 (ja)
GB201206559D0 (en) Polypeptide
WO2015028966A3 (en) Amino diacids containing peptide modifiers
JP2013102146A5 (ja) 化合物
JP2010088434A5 (ja)
JP2014028813A5 (ja)
JP2010065037A5 (ja)
WO2018004308A3 (ko) 신규 내열성 과당-6-인산-3-에피머화 효소 및 이를 이용한 알룰로스 제조방법
JP2012115277A5 (ja)
HRP20171949T1 (hr) Poboljšana veziva za tnf